HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Dyscholesterolemia Protects Against Ischemia-Induced Ventricular Arrhythmias.

AbstractBACKGROUND:
Hypercholesterolemia protects against ventricular fibrillation in patients with myocardial infarction. We hypothesize that hypercholesterolemia protects against ischemia-induced reentrant arrhythmias because of altered ion channel function.
METHODS AND RESULTS:
ECGs were measured in low-density lipoprotein receptor knockout (LDLr(-/-)), apolipoprotein A1 knockout (ApoA1(-/-)), and wild-type (WT) mice. Action potentials, calcium handling, and ion currents were recorded in ventricular myocytes. Gene expression was determined by quantitative polymerase chain reaction and Western blot. In isolated perfused hearts, regional ischemia was induced and arrhythmia inducibility was tested. Serum low-density lipoprotein (LDL) cholesterol was higher in LDLr(-/-) mice than in WT mice (2.6 versus 0.4 mmol/L), and high-density lipoprotein cholesterol was significantly lower in ApoA1(-/-) mice than in WT mice (0.3 versus 1.8 mmol/L). LDLr(-/-) and ApoA1(-/-) myocytes contained more cholesterol than WT (34.4±2.8 and 36.5±2.4 versus 25.5±0.4 μmol/g protein). The major potassium currents were not different in LDLr(-/-) and ApoA1(-/-) compared with WT mice. The L-type calcium current (I(Ca)), however, was larger in LDLr(-/-) and ApoA1(-/-) than in WT (12.1±0.7 and 12.8±0.8 versus 9.4±1.1 pA/pF). Calcium transient amplitude and fractional sarcoplasmic reticulum calcium release were larger and action potential and QTc duration longer in LDLr(-/-) and ApoA1(-/-) than in WT mice (action potential duration at 90% of repolarization: 102±4 and 106±3 versus 84±3.1 ms; QTc: 50.9±1.3 and 52.8±0.8 versus 43.5±1.2 ms). During ischemia, ventricular tachycardia/ventricular fibrillation inducibility was larger in WT than in LDLr(-/-) and ApoA1(-/-) hearts. Expression of sodium channel and Ca-handling genes were not significantly different between groups.
CONCLUSIONS:
Dyscholesterolemia is associated with action potential prolongation because of increased I(Ca) and reduces occurrence of reentrant arrhythmias during ischemia.
AuthorsAntonius Baartscheer, Cees A Schumacher, Vincent Wekker, Arie O Verkerk, Marieke W Veldkamp, Ralph J van Oort, Ies Elzenaar, Roelof Ottenhoff, Cindy van Roomen, Hans Aerts, Ruben Coronel
JournalCirculation. Arrhythmia and electrophysiology (Circ Arrhythm Electrophysiol) Vol. 8 Issue 6 Pg. 1481-90 (Dec 2015) ISSN: 1941-3084 [Electronic] United States
PMID26429563 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright© 2015 American Heart Association, Inc.
Chemical References
  • Apolipoprotein A-I
  • Calcium Channels, L-Type
  • Cholesterol, HDL
  • Cholesterol, LDL
  • Receptors, LDL
  • Sphingolipids
  • Calcium
Topics
  • Action Potentials
  • Animals
  • Apolipoprotein A-I (deficiency, genetics)
  • Calcium (metabolism)
  • Calcium Channels, L-Type (genetics, metabolism)
  • Calcium Signaling
  • Cholesterol, HDL (blood)
  • Cholesterol, LDL (blood)
  • Disease Models, Animal
  • Electrocardiography
  • Female
  • Gene Expression Regulation
  • Heart Rate
  • Hypercholesterolemia (complications, genetics, metabolism, physiopathology)
  • Isolated Heart Preparation
  • Male
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Myocardial Ischemia (complications, genetics, metabolism, physiopathology)
  • Myocytes, Cardiac (metabolism)
  • Receptors, LDL (deficiency, genetics)
  • Sarcoplasmic Reticulum (metabolism)
  • Sphingolipids (blood)
  • Tachycardia, Ventricular (etiology, genetics, metabolism, physiopathology, prevention & control)
  • Time Factors
  • Ventricular Fibrillation (etiology, genetics, metabolism, physiopathology, prevention & control)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: